US 10568873
Safranal-sorafenib combination therapy for liver cancer
granted A61KA61K31/122A61K31/44
Quick answer
US patent 10568873 (Safranal-sorafenib combination therapy for liver cancer) held by UNITED ARAB EMIRATES UNIVERSITY expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- UNITED ARAB EMIRATES UNIVERSITY
- Grant date
- Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/122, A61K31/44, A61K36/88, A61K9/0019